MGNX
MacroGenics, Inc.
Biotechnology · Healthcare · United States
2.40
close · 2026-10-30
value
22
cheaper than peers22
quality
43
stronger fundamentals43
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 0.87× | 98 |
| earnings yield, 2 years ago | -6.3% | 70 |
| price to book | 3.56× | 48 |
| earnings yield, 1 year ago | -44.6% | 27 |
| earnings yield, 3 years ago | -81.3% | 23 |
| earnings yield, latest year | -49.2% | 23 |
| cash flow yield, 1 year ago | -47.1% | 19 |
| cash flow yield, 2 years ago | -52.3% | 19 |
| cash flow yield, latest year | -54.3% | 16 |
| cash flow yield, 3 years ago | -59.3% | 16 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 378.0% | 90 |
| operating margin | -42.2% | 64 |
| debt to equity | 81.9% | 25 |
| return on equity | -225.8% | 10 |
4 of 4 measures available
Facts
| market cap | $153M |
| free cash flow | -$69.4M |
| employees | 293 |
| first trade | 2013-10-10 |
| next earnings | not reported |
| fundamentals updated | 2026-08-20 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.18 | -1.07 | -0.15 | -1.95 |
| free cash flow | -$83.0M | -$72.1M | -$80.0M | -$90.6M |
| net income | -$74.6M | -$67.0M | -$9.1M | -$119.8M |
| revenue | $149.5M | $150.0M | $58.7M | $150.0M |
| unusual items | $0 | $36.3M | $150.9M | $0 |